

I hereby certify that this correspondence is being transmitted via the Office electronic filing system to the U.S. Patent and Trademark Office on the date shown below.

Dated: December 21, 2009

Signature: /Mark D. Russett/  
Mark D. Russett, Reg. No.: 41,281

Docket No.: 65517(53196)  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Anne-Sophie Bessis et al.

Application No.: 10/578,589

Confirmation No.: 9455

Filed: December 13, 2006

Art Unit: 1625

For: ALLOSTERIC MODULATORS OF  
METABOTROPIC GLUTAMATE  
RECEPTORS

Examiner: T. A. Solola

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir/Madam:

In accordance with 37 CFR 1.97, Applicant(s) hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 CFR 1.98(a)(2) accompany this statement.

Applicants have become aware of documents AA-AB, BA-BN, and CA-CE (as cited on the enclosed PTO Form SB/08), cited in two Oppositions (citations CF and CG of the enclosed PTO Form SB/08) filed in connection with granted European (EPO) Patent No. EP1685105B1, which corresponds to the above referenced application, and in accordance with 37 CFR 1.97(c) and (e)(1) or (b)(3), hereby submit these documents for the Examiner's consideration. These documents are cited on the enclosed PTO Form SB/08, and a copy of each document required under 37 CFR 1.98(a)(2) cited thereon, including the Oppositions, is enclosed as well.

A concise explanation of relevance of the items listed on form PTO/SB/08 is given for only non-English language listed items: The Opposition filed on behalf of Sanofi-Aventis (citation CF) seeks revocation of EPO Patent No. EP1685105B1 and alleges that, according to EPO practice: certain claims of the EPO patent are not entitled to the priority date claimed; the EPO patent does not provide sufficient

disclosure to enable the skilled person to perform the inventions of certain claims; certain claims of the EPO patent contain improper disclaimers or are otherwise contrary to EPO Article 123(2); and the claims of the EPO patent lack novelty and/or inventive step in view of the cited references (D1-D15 listed in citation CF; citations AA-AB, BA-BH and CA-CE on the enclosed PTO Form SB/08).

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicants understand the Examiner will make an independent evaluation of the cited documents.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

Please charge our Deposit Account No. 04-1105 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 65517(53196).

Dated: December 21, 2009

Respectfully submitted,

By: /Mark D. Russett/

Mark D. Russett, Registration No.: 41,281  
EDWARDS ANGELL PALMER & DODGE LLP  
P.O. Box 55874  
Boston, Massachusetts 02205  
(617) 239-0100  
Attorneys/Agents For Applicants